Literature DB >> 8613131

Aggressive non-Hodgkin's lymphoma: T-cell versus B-cell.

R Liang1, D Todd, F C Ho.   

Abstract

This study is aimed to define the clinical characteristics, treatment of outcome and independent prognostic factors of 144 patients with T- and 357 B-cell non-Hodgkin's lymphomas. Entities with well-defined immunophenotype and clinical characteristics were excluded. Patients with T-cell tumours were younger. T-immunophenotype was associated with more advanced disease and presence of B symptoms. They were also less likely to have bulky disease. Primary nasal lymphomas were usually T-cell while lymphomas arising from the gastrointestinal tract and Waldeyer's ring were mostly B-cell. On univariate analysis, T-immunophenotype was associated with lower CR rate, higher relapse rate and inferior overall survival. On the other hand, multivariate analysis revealed that advanced stage, presence of B symptoms, advanced age, high serum lactate dehydrogenase level and use of non-doxorubicin-containing regimens for induction were associated with poor prognosis. Immunophenotype was not a significant independent prognostic factor.

Entities:  

Mesh:

Year:  1996        PMID: 8613131     DOI: 10.1002/(SICI)1099-1069(199603)14:1<1::AID-HON555>3.0.CO;2-Y

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  3 in total

1.  Colonic lymphoma presenting acutely with perforated colo-splenic fistula.

Authors:  Ali Ahmed Al-Zahir; Abdul-Wahed Nasir Meshikhes
Journal:  Int J Surg Case Rep       Date:  2012-04-27

2.  Primary colorectal lymphoma: An overview.

Authors:  Goran Z Stanojevic; Milica D Nestorovic; Branko R Brankovic; Miroslav P Stojanovic; Milan M Jovanovic; Milan D Radojkovic
Journal:  World J Gastrointest Oncol       Date:  2011-01-15

3.  Primary T-cell lymphoma associated with tubulovillous adenoma of the rectum: report of a case.

Authors:  Harunobu Sato; Kazuhiko Yasumi; Yoshihisa Mizuno; Tomonari Ichikawa; Katsuyuki Honda; Makoto Kuroda
Journal:  Surg Today       Date:  2012-08-25       Impact factor: 2.549

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.